TELA Bio (TELA) Projected to Post Quarterly Earnings on Tuesday

TELA Bio (NASDAQ:TELA) is expected to be posting its Q4 2025 results after the market closes on Tuesday, March 24th. Analysts expect TELA Bio to post earnings of ($0.18) per share and revenue of $21.0410 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:30 PM ET.

TELA Bio Trading Down 0.5%

NASDAQ TELA opened at $0.74 on Tuesday. TELA Bio has a one year low of $0.67 and a one year high of $2.48. The company’s 50 day moving average price is $0.89 and its 200 day moving average price is $1.18. The company has a debt-to-equity ratio of 26.65, a quick ratio of 2.62 and a current ratio of 3.30. The firm has a market capitalization of $29.68 million, a price-to-earnings ratio of -0.83 and a beta of 0.88.

Hedge Funds Weigh In On TELA Bio

A number of institutional investors have recently added to or reduced their stakes in TELA. Citadel Advisors LLC lifted its stake in shares of TELA Bio by 161.3% in the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock worth $53,000 after acquiring an additional 21,781 shares in the last quarter. XTX Topco Ltd acquired a new stake in TELA Bio during the 4th quarter valued at approximately $48,000. Susquehanna International Group LLP increased its holdings in TELA Bio by 551.2% during the 3rd quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after purchasing an additional 72,594 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of TELA Bio by 101.4% in the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after purchasing an additional 64,800 shares in the last quarter. Institutional investors and hedge funds own 94.35% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on TELA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of TELA Bio in a research report on Thursday, January 22nd. Lake Street Capital restated a “buy” rating on shares of TELA Bio in a report on Monday, December 1st. Loop Capital set a $3.00 price target on shares of TELA Bio in a research report on Monday, December 1st. Finally, Canaccord Genuity Group lowered their price target on TELA Bio from $7.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.25.

TELA Bio Company Profile

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.